Item 8.01 Other Events. OnJanuary 12, 2022 ,Ocugen, Inc. issued a press release announcing the results from a study conducted atEmory University demonstrating that sera from subjects who received a booster dose of the candidate vaccine COVAXIN™ (BBV152) six months after getting a primary two-dose series of COVAXIN™ neutralized the SARS-CoV-2 Omicron and Delta variants. A copy of this press release is filed herewith as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. Item 9.01 Financial Statements and Exhibits. The following exhibits are being filed herewith: (d) Exhibits Exhibit No. Document 99.1 Press Release ofOcugen, Inc. datedJanuary 12, 2022 . Cover Page Interactive Data File (embedded within the Inline XBRL 104 document). 1
--------------------------------------------------------------------------------
© Edgar Online, source